BioXcel Therapeutics, Inc. entered into a Third Amendment to Credit Agreement and Guaranty, waiving the covenant that the company shall not receive a going concern qualification from auditors, and announced the FDA's Fast Track designation for the investigation of BXCL701 for the treatment of metastatic small cell neuroendocrine prostate cancer.